CEL-SCI Corp. CVM 深 沪
已收盘 12-19 16:00:00 美东时间
4.91
-0.590
-10.73%
华盛通- 最 高5.55
- 今 开5.44
- 成交量 16.12万股
- 最 低 4.80
- 昨 收 5.50
- 总市值 3924.76万
- 52周最高 20.409
- 市盈率 静 --
- 换手率 2.02%
- 52周最低 1.98
- 委 比 0.00%
- 总股本 799.34万
- 历史最高 1425.00
- 量 比 3.05
- 振 幅 13.64%
- 历史最低 4.80
- 每 手 1
- 风险率 3.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多自研进阶｜长安汽车“车路云一体化”虚实融合多智能体场景验证平台接受全球检验
在汽车产业向全面智能化、网联化加速迈进的关键历史节点，长安汽车（Changan Automobile）在中国汽车工程学会年会暨展览会（SAECCE 2025）期...
10-25 19:02
Zoetis Announces Committee For Veterinary Medicinal Products Of The EMA Has Adopted A Positive Opinion Recommending The Granting Of Marketing Authorization For Lenivia For The Reduction Of Pain Associated With Osteoarthritis In Dogs
Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for
10-11 04:16
Jaguar Health Receives Notice Of $250K Grant From FDA's Center For Veterinary Medicine To Support Confirmatory Study For Canalevia-CA1 For Chemotherapy-Induced Diarrhea In Dogs
Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) of a $250,000 grant.
09-25 21:05
蔚来资本入局！海德氢能完成新一轮战略融资
全球绿电制氢领域的领先企业海德氢能（HydoTech）今日宣布完成新一轮战略融资，由蔚来资本等机构投资，老股东襄禾资本、愉悦资本持续加码，其中，蔚来资本的部分投...
09-15 15:49
首发｜海德氢能完成新一轮战略融资，专注绿电制氢
原标题：首发｜海德氢能完成新一轮战略融资，专注绿电制氢 投资界（ID：pedaily2012）9月15日消息，绿电制氢领域企业海德氢能（HydoTech）今日...
09-15 10:53
Aura Minerals to Delist From Toronto Exchange, Consolidate Trading on Nasdaq
Aura Minerals Inc. (NASDAQ:AUGO) (TSX:ORA) (B3: AURA33) ("Aura" or the "Company") today announced that its application for a voluntary delisting (the "Delisting") of its common shares (each a "Common Share") from the
09-08 18:10
Reported Saturday, BridgeBio's Attruby/BEYONTTRA Reports Significant 42-Month CV Mortality Reduction In ATTRibute-CM Open Label Extension
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM- Acoramidis also
09-02 15:50
中金：维持信达生物跑赢行业评级 上调目标价至118.3港元
中金发布研报称，考虑到信达生物（01801）上半年运营盈利能力超预期，上调2025年净利润预测84.3%至8.71亿元，基本维持2026年归母净利润预测1...
08-29 11:59
CEL-SCI股价重挫逾30%，此前宣布完成1000万美元公开发行定价
美股周四早盘，生物技术公司CEL-SCI（CVM）股价重挫30.44%，此前该公司宣布完成1000万美元公开发行定价，以每股9.00美元的价格出售1111...
08-28 22:51
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Shares of Snowflake Inc. (NYSE:SNOW) rose sharply in pre-market trading after t...
08-28 17:48
